Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt de Vlam

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Best Practice & Research. Clinical Rheumatology|November 2, 2010
Soluble and tissue biomarkers in ankylosing spondylitisKurt de Vlam
Best Practice & Research. Clinical Rheumatology|March 14, 2026
The promise of biomarkers in Psoriatic Arthritis: Moving towards precision medicineMyroslava Kulyk, Kurt De Vlam
Seminars in Arthritis and Rheumatism|July 3, 2016
SAPHO: Treatment options including bisphosphonatesTom Zwaenepoel, Kurt de Vlam
Expert Review of Clinical Immunology|May 19, 2010
Update in treatment options for psoriatic arthritisKurt de Vlam, Rik J Lories
Current Rheumatology Reports|April 25, 2012
Is psoriatic arthritis a result of abnormalities in acquired or innate immunity?Rik J Lories, Kurt de Vlam
Expert Opinion on Biological Therapy|November 5, 2014
Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicityRik J Lories, Kurt de Vlam
Current Rheumatology Reports|July 30, 2008
Remission in psoriatic arthritisKurt de Vlam, Rik J U Lories
The Journal of Rheumatology|July 15, 2024
Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now?Vinod Chandran, Wilson Liao, Kurt de Vlam
Clinical and Experimental Rheumatology|September 9, 2016
Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanerceptKurt de Vlam, Jacques Bruhwyler, Caroline Boone, et al.
RMD Open|September 22, 2016
Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohortNaba Haque, Rik J Lories, Kurt de Vlam
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Best Practice & Research. Clinical Rheumatology|November 2, 2010
Soluble and tissue biomarkers in ankylosing spondylitisKurt de Vlam
Best Practice & Research. Clinical Rheumatology|March 14, 2026
The promise of biomarkers in Psoriatic Arthritis: Moving towards precision medicineMyroslava Kulyk, Kurt De Vlam
Seminars in Arthritis and Rheumatism|July 3, 2016
SAPHO: Treatment options including bisphosphonatesTom Zwaenepoel, Kurt de Vlam
Expert Review of Clinical Immunology|May 19, 2010
Update in treatment options for psoriatic arthritisKurt de Vlam, Rik J Lories
Current Rheumatology Reports|April 25, 2012
Is psoriatic arthritis a result of abnormalities in acquired or innate immunity?Rik J Lories, Kurt de Vlam
Expert Opinion on Biological Therapy|November 5, 2014
Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicityRik J Lories, Kurt de Vlam
Current Rheumatology Reports|July 30, 2008
Remission in psoriatic arthritisKurt de Vlam, Rik J U Lories
The Journal of Rheumatology|July 15, 2024
Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now?Vinod Chandran, Wilson Liao, Kurt de Vlam
Clinical and Experimental Rheumatology|September 9, 2016
Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanerceptKurt de Vlam, Jacques Bruhwyler, Caroline Boone, et al.
RMD Open|September 22, 2016
Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohortNaba Haque, Rik J Lories, Kurt de Vlam
Pageof 14